Elan Corporation, plc (ADR) (ELN) Received Buyout Bid Before Buyback

Page 1 of 2

When Elan Corporation, plc (ADR) (NYSE:ELN) sold its stake in the blockbuster selling multiple sclerosis drug Tysabri to partner Biogen Idec Inc. (NASDAQ:BIIB) in early February, many investors at both companies were left questioning the deal and the motive.

Dublin, Ireland based Elan pocketed $3.25 billion in the sale (on which it will pay little tax) and also inked a royalty payment plan for future sales of the dynamic drug. The hefty payout resulted in a credit downgrade for drug behemoth Biogen, despite the fact it gained sole control over the effective MS treatment. It’s yet to be seen who the clear winner is in this arrangement but Biogen obviously sees big things for Tysabri, which brought in some $1.6 billion in sales in 2012 alone.

Elan Corporation, plc (ADR) (NYSE:ELN)What Elan PLans to Do With the Payout

Analysts and investors have been clamoring for news regarding what Elan intends to do with the hefty takings and now they have some answers. In addition to the $1 billion share buyback announced Feb. 22, the company intends to engage in “a number a strategic transactions” with a share of the proceeds, according to a statement. It will also refinance its $600 million in debt.

Elan CEO Kelly Martin said in a statement, “Understandably, many market participants are looking forward to further clarity around how we intend to deploy the significant upfront payment we will be receiving. We have been making significant progress in this regard and are prepared to move expeditiously, upon close, on the redeployment of capital.”

The share buyback may appease some investors who viewed the Tysabri deal with skepticism. So much so, they sent shares reeling the day the deal was announced it what was the stock’s biggest slide in seven months. At the time Elan said it would share some proceeds with shareholders, but didn’t go into detail.

London’s Breenberg Bank analyst Adrian Howd told Bloomberg, “They’ve now put some numbers around that. And it looks as if the timing of the use of other proceeds, in term of investments in pipeline and new products, is more progressed than some had thought.” Howd recommends buying Elan shares.

Shedding Assets

Elan has been cleaning house. The now stripped-down, streamlined company sold its Elan Drug Technologies unit to Alkermes in 2011. Last December, it spun off Prothena Corporation PLC (NASDAQ:PRTA), its early stage drug research company. Elan surmises the two separated companies will each be worth more apart than conjoined.

Prothena is focused on the discovery and development of antibodies to treat myriad diseases. More specifically it researches disease causing proteins. Potential therapies can be used to treat ailments such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. The company’s aim is to apply its extensive expertise in generating novel antibodies and then work with strategic partners to eventually bring their findings to clinical trails.

Prothena CEO Dale Schenk said after the spin-off, but before the Tysabri sale, that the promise of Prothena’s drug pipeline “will be more visible to investors now that the company is out from under the umbrella of the Tysabri effort.” Who knew the hit drug was such a drag?

Elan’s Future and Fate

No doubt some investors believed Elan would use the proceeds from the Biogen and Alkermes sale to fund research on its Alzheimer’s disease treatments. Elan is working with giants Johnson & Johnson (NYSE:JNJ) and Pfizer Inc. (NYSE:PFE) on a drug for the dementia-like progressive ailment that causes problems with memory, thinking and behavior. In the U.S., the disease affects more than 5 million, or one in eight, a number that is expected to swell in the near future.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!